Perioperative application of the Viscum album extract Isorel in digestive tract cancer patients

Anticancer Research

Volumn 25, Issue 6 C, 2005, Pages 4583-4590

  Enesel, Mircea Bogdan ^a,b   Acalovschi, Iurie ^c   Grosu, Vasile ^d   Sbarcea, Adriana ^d   Rusu, Catrinel ^d   Dobre, Adrian ^b   Weiss, Thomas ^e   Zarkovic, Neven ^f  

^a 2nd Anesth and IC Department   (Romania)

^b Emergency Hospital   (Romania)

^c IULIU HATIEGANU UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^d Clinical Hospital Dimitrie Gerota   (Romania)

^e Novipharm GmbH   (Austria)

^f RUDER BO KOVI INSTITUTE   (Croatia)

Author keywords

Biotherapy; Immune suppression; Immunomodulation; Isorel; Mistletoe; NK cells; T helper cells; Viscum album

Indexed keywords

COMPLEMENT COMPONENT C3; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; VISCUM ALBUM EXTRACT;

ADULT; AGED; ARTICLE; B LYMPHOCYTE; CANCER ADJUVANT THERAPY; CANCER CELL; CANCER PATIENT; CELLULAR IMMUNITY; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIGESTIVE SYSTEM CANCER; DRUG CYTOTOXICITY; ESOPHAGUS CANCER; FEMALE; HEALTH STATUS; HELPER CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; HUMORAL IMMUNITY; ILEUM CANCER; IMMUNOCOMPETENCE; IMMUNOMODULATION; MALE; NATURAL KILLER CELL; PANCREAS CANCER; PARAMETER; PERIOPERATIVE PERIOD; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; STOMACH CANCER; T LYMPHOCYTE; VALIDATION PROCESS; VISCUM ALBUM;

ADULT; AGED; AGED, 80 AND OVER; CD4-CD8 RATIO; CD8-POSITIVE T-LYMPHOCYTES; COMBINED MODALITY THERAPY; COMPLEMENT C3; DIGESTIVE SYSTEM NEOPLASMS; FEMALE; HUMANS; IMMUNOGLOBULIN A; IMMUNOGLOBULIN M; LEUKOCYTE COUNT; LEUKOCYTES; MALE; MIDDLE AGED; PERIOPERATIVE CARE; PLANT EXTRACTS; PROSPECTIVE STUDIES; T-LYMPHOCYTES, HELPER-INDUCER; VISCUM ALBUM;

EID: 28444482002     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. Carstens JH: November 2, 1901. The requirements of modern surgery. JAMA 100 Years Ago 17: 286, 2001.
2. McBride WT: Immunomodulation: an important concept in modern anesthesia. Anesthesia 51: 465-473, 1996.
3. Stevenson GW, Steven GH and Steven RBA: The effect of anesthetic agents on the human immune response. Anesthesiology 72: 542-552, 1990.
4. Rebuck JA, Bergman KL, Pirucello SJ and Olsen KN: In vivo effects of Ranitidine and Omeprazole on T-lymphocyte proliferation and immunomodulation. Soc Crit Care Med 551: 2001.
5. De Leon-Casasola O: Immunomodulation and epidural anesthesia and analgesia. Region Anesth 21: 65, 1996.
6. Lont HE: Blood transfusion: what does it mean to the surgeon? Digest Surg 14: 2-8, 1997.
7. Steiner R: Spiritual Sciences and Medicine. London, Rudolf Steiner Publishing Co., 1920.
8. Kanner L: Mistletoe, magic and medicine. Bull Hist Med 7: 875-883, 1939.
9. Khwaja TA, Dias CB, Pentecost S and Papoian H: Studies on cytotoxic and immunologic effects of Viscum album (mistletoe). Proc Am Ass Cancer Res 22: 153-162, 1981.
10. Franz H: Request for an impartial discussion of the so/called mistletoe therapy. Oncology 43(suppl.1): 1-15, 1986.
11. Kissel D, Jurin M and Zarkovic N: Uber die kompinierte Tumortherapie: Eine experimentelle Studie uber die Wirksamkeit von Viscum album. Dtch Zsch Onkol 22: 134-136, 1990.
12. Kleijnen J and Knipschild P: Mistletoe treatment for cancer: review of controlled trials in humans. Phytomedicine 1: 255-260, 1994.
13. Bussing A: Mistletoe: a story with an open end. Anti Cancer Drugs 8(suppl.1): 1-2, 1997.
14. Klamerth O, Vester F and Kellner G: Inhibitory effects of a protein complex from Viscum album on fibrobalsts and HeLa cells. Hope-Seyler's Z Physio Chem 349: 863-870, 1968.
15. Jung ML, Baudino S, Ribereau-Gayon G and Beck JP: Characterization of cytotoxic proteins from mistletoe (Viscum album L.). Cancer Lett 51: 103-114, 1990.
16. Samuelsson G: Mistletoe toxins. Syst Zool 22: 566-571, 1974.
17. Hulsen H and Mechelke F: In vitro effectiveness of a mistletoe preparation on cytostatic-drug-resistant human leukemia cells. Naturwiss 74: 144-152, 1987.
18. Kissel D, Jurin M and Zarkovic N: Uber die zytostatischen und immunologishen effecte von Viscum album. Erfahrungscheilkunde 39: 59-63, 1990.
19. Jurin M, Zarkovic N, Hrzenjak M and Ilic Z: Antitumorous and immunomodulatory effects of Viscum album preparation Isorel. Oncology 50: 393-398, 1993.
20. Hulsen H, Kron R and Mechelke F: Influence of Viscum album preparation on the natural killer cell-mediated cytotoxicity of peripheral blood. Naturwiss 76: 530-535, 1989.
21. Hajto T, Hostanska K and Gabius HJ: Modulatory potency of the β-galacotside-specific lectin from mistletoe extract (Iscador) on the host defense system in vivo in rabbits and patients. Cancer Res 49: 4803-4814, 1989.
22. Männel DN, Becker H, Gundt A, Kist A and Franz H: Induction of tumor necrosis factor expression by lectin from Viscum album. Cancer Immunol Immunother 33: 177-184, 1991.
23. Ganguly C and Das S: Plant lectins as inhibitors of tumor growth and modulators of host immune response. Chemotherapy 40: 272-278, 1994.
24. Beuth J, Ko HL, Tunggal L, Buss G, Jeljasewitz J, Steur MK and Pulverer G: Immunoaktive Wirkung von Mistellektin-I in abhangigkeit von Dosierung. Arznem-Forsch/Drug Res 44: 21-25, 1994.
25. Olsems S, Stripe F, Sandevig K and Phil A: Isolation and characterization of viscumin, a toxic lectin from Viscum album L. (mistletoe). J Biol Chem 257: 1326-1334, 1982.
26. Heiny BM and Beuth J: Mistletoe extract standardized for the galactoside-specific lectin (ML-I) induces beta-endorphin release and immunopotentiation in breast cancer patients. Anticancer Res 14: 1339-1342, 1994.
27. Beuth J: Clinical relevance of immunoactive mistletoe lectin-1. Anti-Cancer Drugs 8(suppl1): 53-56, 1997.
28. Cazacu M, Oniu T, Lungoci C, Mihailov A, Cipak A, Klinger R, Weiss T and Zarkovic N: The influence of isorel on the advanced colorectal cancer. Cancer Bioth Radipharm 18: 27-34, 2002.
29. Zarkovic N, Jurin M, Dittrich W, Hartleb M, Sladlojev S and Kissel D: Comparison of the antitumorous effects of Viscum album lectins and the plain or fractional fresh plant preparation Isorel. In: Grundlagen der Misteltherapie. Scheer R, Becker H and Berg PA (eds.), Suttgart, Hippokrates Verlag, pp. 325-338, 1996.
30. Zarkovic N, Kalisnik T, Loncaric I, Borovic S, Mang S, Kissel D, Konitzer M, Jurin M and Grainza S: Comparison of the effects of Viscum album lectin ML-1 and fresh plant extract (ISOREL) on the cell growth in vitro and tumorigenicity of melanoma B16F10. Cancer Bioth Radipharm 13: 121-131, 1998.
31. Schumacher K, Schneider B, Reich G, Stiefel T, Stoll G, Bock PR, Hanisch J and Beuth J: Influence of postoperative complementary treatment with lectin-standardized mistletoe extract on breast cancer patients. A controlled epidemiological multicentric retrolective cohort study. Anticancer Res 23: 5081-5087, 2003.
32. Piao BK, Wang YX, Xie GR, Mansmann U, Matthes H, Beuth J and Lin HS: Impact of complementary mistletoe extract treatment on quality of life in breast, ovarian and non-small cell lung cancer patients. A prospective randomized controlled clinical trial. Anticancer Res 24: 303-309, 2004.
33. Schoffski P, Riggert S, Fumoleau P, Campone M, Bolte O, Marreaud S, Lacombe D, Baron B, Herold M, Zwierzina H, Wilhelm-Ogunbiyi K, Lentzen H and Twelves C: Phase I trial of intravenous aviscumine (rViscumin) in patients with solid tumors: a study of the European Organization for Research and Treatment of Cancer New Drug Development Group. Ann Oncol 15: 1816-1824, 2004.
34. Mabed M, El-Helw L and Shamaa S: Phase II study of viscum fraxini-2 in patients with advanced hepatocellular carcinoma. Br J Cancer 90: 65-69, 2004.
35. Bock PR, Friedel WE, Hanisch J, Karasmann M and Schneider B: Retrolective, comparative, epidemiological cohort study with parallel groups design for evaluation of efficacy and safety of drugs with 'well-established use' - experience with the long-term treatment using the European mistletoe extract (Viscum album L.) in addition to conventional oncological therapy in primary, non-metastatic breast carcinoma. Forschende Komplementarmedizin und Klassische Naturheilkunde 11(Suppl 1): 23-29, 2004.
36. Semiglasov VF, Stepula VV, Dudov A, Lehmacher W and Mengs U: The standardised mistletoe extract PS76A2 improves QoL in patients with breast cancer receiving adjuvant CMF chemotherapy: a randomised, placebo-controlled, double-blind, multicentre clinical trial. Anticancer Res 24: 1293-1302, 2004.
37. Nicolaisen-Murmann K, Thiel F, Mohrmann S, Grunewald E, Ackermann S, Bender HG, Beckmann MW and Fasching PA: Complementary and alternative medicine in women with gynecological and breast malignancies - a multicenter study exploring prevalence and motivation. Geburtshilfe und Frauenheilkunde 65: 178-185, 2005.
38. Augustin M, Bock PR, Hanisch J, Karasmann M and Schneider B: Safety and efficacy of the long-term adjuvant treatment of primary intermediate- to high-risk malignant melanoma (UICC/AJCC stage II and III) with a standardized fermented European mistletoe (Viscum album L.) extract - results from a multicenter, comparative, epidemiological cohort study in Germany and Switzerland. Arzneimittel-Forschung 55: 38-49, 2005.
39. Bar-Sela G and Haim N: Abnoba-viscum (Mistletoe extract) in metastatic colorectal carcinoma resistant to 5-fluorouracil and leucovorin-based chemotherapy. Med Oncol 21: 251-254, 2004.
40. Kleeberg UR, Suciu S, Brocker EB, Ruiter DJ, Chartier C, Lienard D, Marsden J, Schadendorf D and Eggermont AMM: Final results of the EORTC 18871/DKG 80-1 randomised phase III trial: rIFN-alpha 2b versus rIFN-gamma versus ISCADOR M (R) versus observation after surgery in melanoma patients with either high-risk primary (thickness > 3 mm) or regional lymph node metastasis. Eur J Cancer 40: 390-402, 2004.
41. Zarkovic N and Vukovic T: An overview an anticancer activities of the Viscum album extract ISOREL. Cancer Bioth Radiopharm 16: 55-62, 2001.
42. Zarkovic N and Trbojevic-Cepe M: Comparison of the effects and low concentrations of the separated Viscum album L. lectins and the plain mistletoe plant preparation (ISOREL) on the growth of normal and tumor cells in vitro. Period Biol 97: 61-67, 1995.
43. Beuth J: Immunotherapy with mistletoe lectin-1. A scientific approach. Cancer 8: 1-7, 2001.
44. Pfuller U: Immunmodulation durch Mistelinhaltsstoffe. In: Grundlagen der Misteltherapie. Scheer R, Becker H and Berg PA (eds.), Suttgart, Hippokrates Verlag, pp. 170-182, 1996.
45. Bussing A: Leben und sterben lassen DNA-stabilisierende und zytotoxische Effekte von Viscum album L.-Extracten. In: Grundlagen der Misteltherapie. Scheer R, Becker H and Berg PA (eds.), Suttgart, Hippokrates Verlag, pp. 191-196, 1996.
46. Berg PA and Stein GM: Einfluss einer Misteltherapie auf die Tumorabwehr - Eine kritische immunologische Analyse. In: Die Mistel in der Tumortherapie - Grundlagenforschung und Klinik. Scheer R, Bauer R, Becker H, Berg PA and Fintelmann V (eds.), Essen, KVC Verlag, pp. 95-107, 2001.
47. Heiny BM and Beuth J: Das Lektin der Mistel als Immunmodulator: Effektorwirkung auf β-Endorphin und; Zytokinfreisetzung bei Mammakarzinompatientinnen. Dtch Zsch Onkol 4: 103-108, 1994.
48. Hager ED: Die prognostische Relevanz immunologischer Parameter in der Onkologie. In: Grundlagen der Misteltherapie. Scheer R, Becker H and Berg PA (eds.), Suttgart, Hippokrates Verlag, pp. 419-436, 1996.
49. Fritz P, Dippon J, Kierschke T, Siegle I, Mohring A, Moisa A and Murdter TE: Impact of mistletoe lectin binding in breast cancer. Anticancer Res 24:1187-1192, 2004.